HK56397A - Matrixtablet for the sustained release of indapamide after oral administration - Google Patents

Matrixtablet for the sustained release of indapamide after oral administration

Info

Publication number
HK56397A
HK56397A HK56397A HK56397A HK56397A HK 56397 A HK56397 A HK 56397A HK 56397 A HK56397 A HK 56397A HK 56397 A HK56397 A HK 56397A HK 56397 A HK56397 A HK 56397A
Authority
HK
Hong Kong
Prior art keywords
indapamide
oral administration
matrixtablet
sustained release
release
Prior art date
Application number
HK56397A
Other languages
English (en)
Inventor
Alain Cuine
Bruno Huet De Barochez
David Guez
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of HK56397A publication Critical patent/HK56397A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK56397A 1991-06-18 1997-05-01 Matrixtablet for the sustained release of indapamide after oral administration HK56397A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9107400A FR2677886B1 (fr) 1991-06-18 1991-06-18 Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.

Publications (1)

Publication Number Publication Date
HK56397A true HK56397A (en) 1997-05-09

Family

ID=9413931

Family Applications (1)

Application Number Title Priority Date Filing Date
HK56397A HK56397A (en) 1991-06-18 1997-05-01 Matrixtablet for the sustained release of indapamide after oral administration

Country Status (14)

Country Link
US (1) US5334392A (xx)
EP (1) EP0519820B1 (xx)
JP (1) JP2638389B2 (xx)
AT (1) ATE131050T1 (xx)
AU (1) AU651894B2 (xx)
CA (1) CA2071408C (xx)
DE (1) DE69206495T2 (xx)
DK (1) DK0519820T3 (xx)
ES (1) ES2083119T3 (xx)
FR (1) FR2677886B1 (xx)
GR (1) GR3019017T3 (xx)
HK (1) HK56397A (xx)
IE (1) IE72192B1 (xx)
ZA (1) ZA924482B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018386A1 (en) * 1994-12-14 1996-06-20 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression
AU5609998A (en) * 1997-01-10 1998-08-03 Abbott Laboratories Tablet for the controlled release of active agents
FR2760190B1 (fr) * 1997-02-28 1999-04-09 Adir Composition pharmaceutique pour la liberation programmee de dexfenfluramine
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
PL193976B1 (pl) * 2002-07-01 2007-04-30 Pliva Krakow Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid
WO2004093819A2 (en) 2003-04-21 2004-11-04 Euro-Celtique, S.A. Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
WO2005011682A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経口徐放性錠剤
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
ES2281851T3 (es) * 2003-12-09 2007-10-01 Euro-Celtique S.A. Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
DE102004005009A1 (de) * 2004-01-30 2005-09-01 Krka Tovarna Zdravil, D.D. Verzögert freisetzende pharmazeutische Zusammensetzung von Indapamid
PT1729730E (pt) 2004-03-30 2009-04-06 Euro Celtique Sa Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso
FR2878748B1 (fr) * 2004-12-07 2007-03-09 Arrow Generiques Soc Par Actio Formule de comprimes permettant une liberation prolongee d'indapamide apres administration par voie orale et procede de preparation
DE102004062257A1 (de) 2004-12-23 2006-07-06 Merckle Gmbh Direkt verpresste Indapamid-Tabletten mit verzögerter Wirkstofffreisetzung
US20060182803A1 (en) * 2005-02-17 2006-08-17 Standard Chem. & Pharm. Co., Ltd. Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
US20090264495A1 (en) * 2005-02-17 2009-10-22 Standard Chem. & Pharm. Co., Ltd. Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
EA013472B1 (ru) * 2007-10-19 2010-04-30 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с пролонгированным высвобождением индапамида, способ ее получения и способ лечения
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2380561A1 (en) 2010-04-21 2011-10-26 LEK Pharmaceuticals d.d. Extended release formulation comprising indapamide
US8501009B2 (en) 2010-06-07 2013-08-06 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Fluid purification system
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
AU2012318561B2 (en) 2011-10-07 2017-04-20 Outset Medical, Inc. Heat exchange fluid purification for dialysis system
EP2842711B1 (en) * 2013-08-26 2018-10-10 Airbus Operations GmbH Apparatus and method for producing a composite material aircraft component
CN104324013B (zh) * 2014-10-30 2017-09-26 黄山中皇制药有限公司 吲达帕胺缓释剂的制备工艺
CN111150713B (zh) * 2018-11-07 2023-02-10 珠海润都制药股份有限公司 一种吲达帕胺胶囊及其制备方法
CN112370433A (zh) * 2020-12-07 2021-02-19 石家庄市华新药业有限责任公司 一种吲达帕胺缓释片及其制备方法
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203691A (en) * 1968-03-06 1970-09-03 Science Union & Cie New disubstituted n-amino indoline derivatives and process for preparing them
DE2520978C3 (de) * 1975-05-10 1981-02-19 Hoechst Ag, 6000 Frankfurt Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
AU571312B2 (en) * 1984-02-10 1988-04-14 Nycomed Danmark A/S Diffusion coated multiple-units dosage form
WO1985004099A1 (en) * 1984-03-21 1985-09-26 Key Pharmaceuticals, Inc. Sustained release oral dosage form for naproxyn
HU196125B (en) * 1985-02-05 1988-10-28 Sandoz Ag Process for producing pharmaceutical comprising 3-(aminopropoxy)-indole derivatives combined with diuretic
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
FR2588188B1 (fr) * 1985-10-04 1988-01-08 Delalande Sa Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
IT1187750B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation

Also Published As

Publication number Publication date
EP0519820B1 (fr) 1995-12-06
JPH05186346A (ja) 1993-07-27
FR2677886B1 (fr) 1995-03-31
ZA924482B (en) 1993-08-18
IE72192B1 (en) 1997-03-26
AU651894B2 (en) 1994-08-04
ATE131050T1 (de) 1995-12-15
US5334392A (en) 1994-08-02
GR3019017T3 (en) 1996-05-31
CA2071408C (fr) 2001-06-12
DK0519820T3 (da) 1996-04-22
EP0519820A1 (fr) 1992-12-23
DE69206495T2 (de) 1996-07-25
JP2638389B2 (ja) 1997-08-06
CA2071408A1 (fr) 1992-12-19
IE921952A1 (en) 1992-12-30
DE69206495D1 (de) 1996-01-18
ES2083119T3 (es) 1996-04-01
AU1834392A (en) 1992-12-24
FR2677886A1 (fr) 1992-12-24

Similar Documents

Publication Publication Date Title
HK56397A (en) Matrixtablet for the sustained release of indapamide after oral administration
IL104192A0 (en) Pharmaceutical dosage forms having prolonged release rate of active ingredient
ZA889495B (en) Sustained release pharmaceutical composition
IS3957A (is) Aðferð til framleiðslu á þrýstingsúðasamsetningumtil inntöku lyfja með innöndun
HUT47843A (en) Process for producing pharmaceutical with regulated active ingredient release
IL101795A0 (en) Pharmaceutical tablet formulations
ZA871620B (en) Formulation for preparing sustained release drugs for oral administration
AU8019991A (en) Programmed release oral solid pharmaceutical dosage form
EP0652770A4 (en) ORAL ADMINISTRATION OF ANTIGENS.
HU9402785D0 (en) Paramycin formulations for oral administration
GB9103302D0 (en) Pharmaceutical formulations
ZA887624B (en) Oral formulation of buspirone and salts thereof
ITMI922885A1 (it) Composizioni farmaceutiche a rilascio controllato contenenti nicergolina
NO180450C (no) Farmasöytiske formuleringer og fremgangsmåte for fremstilling av form II diritromycin
GB8801863D0 (en) Pharmaceutical formulations with controlled drug release
IL103411A0 (en) Pharmaceutical formulation for controlled release of melatonin
ATE73662T1 (de) Diphosphonsaeurederivat enthaltendes arzneimittel zur oralen gabe.
IE872675L (en) Sustained release pharmaceutical
ITPD920141A1 (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
ITFI910264A1 (it) Procedimento per la produzione di un bollino farmaceutico od equivalente, e bollino cosi' realizzato
ITBO920455A1 (it) Procedimento per preparare forme farmaceutiche a rilascio controllato ritardato del principio attivo e le forme farmaceutiche cosi' ottenute.
FI941696A (fi) Systeemi lääkkeen oraaliseen antoon
ZA922520B (en) Sustained release capsule and formulations
AU5273993A (en) Oral pharmaceutical administration device
IE900393L (en) Pharmaceutical compositions for oral administration

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120617